Login to Your Account



Clinic Roundup


Friday, March 4, 2011
Infinity Pharmaceuticals Inc., of Cambridge, Mass., started a Phase II trial of IPI-926, an oral molecule designed to inhibit Smoothened, in patients with metastatic or locally advanced inoperable chondrosarcoma. The study is expected to enroll more than 100 patients and will compare IPI-926 to placebo, with progression-free survival as the primary endpoint. Secondary endpoints include time to progression, overall survival, overall response rate and response duration. Infinity also reported that the FDA granted orphan drug status of IPI-926 in chondrosarcoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription